|  |
| --- |
| **Box 2: Criteria for a third primary dose of COVID-19 vaccine in children aged 5-11 years**  **Individuals with primary or acquired immunodeficiency states at the time of vaccination due to conditions including:**   * acute and chronic leukaemias, and clinically aggressive lymphomas (including Hodgkin’s lymphoma) who were under treatment or within 12 months of achieving cure at the time of vaccination * individuals under follow up for a chronic lymphoproliferative disorders including haematological malignancies * children with immunosuppression due to HIV/AIDS (children with a current CD4 count of   <500 cells/*μ*l in those aged 5 years and <200 cells/*μ*l in those aged 6-11 years)   * Primary or acquired cellular and combined immune deficiencies – those with lymphopaenia   (<1,000 lymphocytes/*μ*) or with a functional lymphocyte disorder   * those who had received a stem cell transplant or chimaeric antigen receptor (CAR)-T cell therapy in the 24 months before vaccination * those who had received a stem cell transplant more than 24 months before vaccination but had ongoing immunosuppression or graft versus host disease (GVHD) * persistent agammaglobulinaemia (IgG < 3g/L) due to primary immunodeficiency (e.g. common variable immunodeficiency) or secondary to disease / therapy   **Individuals on immunosuppressive or immunomodulating therapy at the time of vaccination including:**   * those who were receiving immunosuppressive therapy for a solid organ transplant at the time of vaccination * those who were receiving or had received in the previous 3 months targeted therapy for autoimmune disease, such as JAK inhibitors or biologic immune modulators including B-cell targeted therapies (including rituximab but in this case the recipient would be considered immunosuppressed for a 6 month period), T-cell co-stimulation modulators, monoclonal tumour necrosis factor inhibitors (TNFi), soluble TNF receptors, interleukin (IL)-6 receptor inhibitors., IL-17 inhibitors, IL 12/23 inhibitors, IL 23 inhibitors. (Note: this list is not exhaustive) * those who were receiving or had received immunosuppressive chemotherapy or radiotherapy for any indication in the 6 months before vaccination   **Individuals with chronic immune-mediated inflammatory disease who were receiving or had received immunosuppressive therapy prior to vaccination including:**   * high dose corticosteroids (equivalent to ≥ 1mg prednisolone per kg per day) for more than 10 days in the month before vaccination * long term moderate dose corticosteroids (equivalent to ≥ 0.5 mg prednisolone per kg per day for more than 4 weeks) in the 3 months before vaccination * any dose of non-biological oral immune modulating drugs (with the exception of hydroxchloroquine and sulfasalzine), such as methotrexate, azathioprine, 6-mercaptopurine or mycophenolate in the 3 months before vaccination. (Note: this list is not exhaustive)   **Individuals who had received high dose steroids (equivalent to >2mg prednisolone per kg per day for more than a week) for any reason in the month before vaccination** |